Dudediligence.

MeiraGTx Holdings plc

MGTXNASDAQ · Biological Products, (No Diagnostic Substances)
Write an idea

Insiders

Last 12 months

Sales planned on beside the trades reported on , and whether each names a .

Planned ·

$4,693,680

10 notices · 452,479 sh

Oct 2025 to Oct 2026

Reported ·

$2,470,592

6 sales · 0 buys

Oct 2025 to Jun 2026

The two figures cover different periods.

All 6 reported sales carry the 10b5-1 box. Together they are 0.29% of the shares on issue.

PLANNED · FORM 144Oct 2025 to Oct 2026REPORTED · FORM 4Oct 2025 to Jun 2026N2025DJ2026FMAMJJASO2026-10-06: Naylor Stuart, Form 1442026-08-18: Alexandria Forbes, Form 1442026-07-21: Richard Giroux, Form 1442026-07-07: Naylor Stuart, Form 1442026-05-19: Alexandria Forbes, Form 1442026-04-21: Richard Giroux, Form 1442026-04-07: Naylor Stuart, Form 1442026-03-24: Alexandria Forbes, Form 1442025-10-21: Richard Giroux, Form 1442025-10-07: Alexandria Forbes, Form 1442025-10-07: Forbes Alexandria, sold2025-10-21: Giroux Richard, sold2026-03-24: Forbes Alexandria, sold2026-04-07: Naylor Stuart, sold2026-04-21: Giroux Richard, sold2026-05-19: Forbes Alexandria, sold
under a ▼ salesize is dollars

Form 144 notices, newest first

2026-10-06Naylor Stuart, CHIEF SCI OFCR, OPHTHALMOLOGY$294,321
27,659 shplan 2025-12-09Form 4s on file end Jun 23144 ↗
2026-08-18Alexandria Forbes, PRESIDENT & CEO$859,320
62,000 shplan 2025-11-18Form 4s on file end Jun 23144 ↗
2026-07-21Richard Giroux, CFO & COO$700,560
56,000 shplan 2025-11-18Form 4s on file end Jun 23144 ↗
2026-07-07Naylor Stuart, CHIEF SCI OFCR, OPHTHALMOLOGY$368,694
27,659 shplan 2025-12-09Form 4s on file end Jun 23144 ↗
2026-05-19Alexandria Forbes, PRESIDENT & CEO$568,540
62,000 shplan 2025-11-18144 ↗
Form 4, 2026-05-19: sold 62,000 at $9.17The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2025. Form 4 ↗
2026-04-21Richard Giroux, CFO & COO$572,545
56,000 shplan 2025-11-18144 ↗
Form 4, 2026-04-21: sold 56,000 at $10.22The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2025. Form 4 ↗
2026-04-07Naylor Stuart, CHIEF SCI OFCR, OPHTHALMOLOGY$258,875
27,661 shplan 2025-12-09144 ↗
Form 4, 2026-04-07: sold 27,661 at $9.36The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 9, 2025. Form 4 ↗
2026-03-24Alexandria Forbes, PRESIDENT & CEO$459,420
62,000 shplan 2025-11-18144 ↗
Form 4, 2026-03-24: sold 62,000 at $7.41 Form 4 ↗
2025-10-21Richard Giroux, CFO & COO$212,880
24,000 shplan 2024-08-29144 ↗
Form 4, 2025-10-21: sold 24,000 at $8.87 Form 4 ↗
2025-10-07Alexandria Forbes, PRESIDENT & CEO$398,525
47,500 shplan 2024-08-21144 ↗
Form 4, 2025-10-07: sold 47,500 at $8.39 Form 4 ↗